Study of DNA Samples From Patients With Multiple Myeloma

ECOG-ACRIN Cancer Research Group

Status

Completed

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Treatments

Genetic: polymorphism analysis

Study type

Observational

Funder types

NETWORK

NIH

Identifiers

NCT00898040

CDR0000495284

ECOG-E3L06T1

Details and patient eligibility

About

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.

Full description

OBJECTIVES:

Determine whether there is an increased frequency of 1 or more polymorphic alleles that are associated with clinical endpoints using custom myeloma single nucleotide polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple myeloma.
Determine SNPs associated with toxicities caused, not by variations in tumor cell genetics, but by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME).
Determine SNPs associated with response, influenced by the same ADME.
Determine SNPs associated with bone disease (as a variable) among patients with multiple myeloma.
Determine SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma).

OUTLINE: This is a retrospective, multicenter study.

Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and response.

PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.

Enrollment

600 patients

Sex

All

Ages

18 to 120 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS: